作者|黄宇晨编辑| 方 乔近期,上海医药对外发布公告称,其将以不低于10.23亿元人民币的底价,借助公开挂牌的途径,转让持有的中美上海施贵宝制药有限公司(以下简称“中美施贵宝”)30%的股权。此前,在2025年9月,百时美施贵宝(BMS)已同高瓴资本关联方达成协议,计划出让所持的60%股权。待两笔交易整合完成,高瓴将斥资4.8亿美元,全面收购这家创立于1982年的中美老牌合资药企。会计师事务所...
Source Link作者|黄宇晨编辑| 方 乔近期,上海医药对外发布公告称,其将以不低于10.23亿元人民币的底价,借助公开挂牌的途径,转让持有的中美上海施贵宝制药有限公司(以下简称“中美施贵宝”)30%的股权。此前,在2025年9月,百时美施贵宝(BMS)已同高瓴资本关联方达成协议,计划出让所持的60%股权。待两笔交易整合完成,高瓴将斥资4.8亿美元,全面收购这家创立于1982年的中美老牌合资药企。会计师事务所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.